Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19 CAR T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma
NCT03434769Phase 1Active, not recruiting
- Start
- Jul 2018
- Primary completion
- Mar 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19 CAR-T cells in non-Hodgkin lymphoma (NHL). Primary endpoint: Objective Response Rate at 12 months. Started Jul 2018; status: active, not recruiting.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03434769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03434769.